Assessment of the Effect of Sorafenib on Omega-6 and Omega-3 Epoxyeicosanoid Formation in Patients with Hepatocellular Carcinoma

@article{Leineweber2020AssessmentOT,
  title={Assessment of the Effect of Sorafenib on Omega-6 and Omega-3 Epoxyeicosanoid Formation in Patients with Hepatocellular Carcinoma},
  author={Can G Leineweber and Anne Pietzner and Ingrid W Zhang and U. Blessin and M. Rothe and E. Schott and N. H. Schebb and K. Weylandt},
  journal={International Journal of Molecular Sciences},
  year={2020},
  volume={21}
}
  • Can G Leineweber, Anne Pietzner, +5 authors K. Weylandt
  • Published 2020
  • Medicine
  • International Journal of Molecular Sciences
  • Hepatocellular carcinoma (HCC) is a leading cause of cancer death. The multikinase inhibitor sorafenib is widely used for systemic therapy in advanced HCC. Sorafenib might affect epoxyeicosanoids, as it is also a potent inhibitor of the soluble epoxide hydrolase (sEH), which catalyzes the conversion of epoxides derived from long-chain polyunsaturated fatty acids (PUFAs), such as arachidonic acid (AA) and omega-3 docosahexaenoic acid (DHA), into their corresponding diols. Experimental studies… CONTINUE READING
    5 Citations

    References

    SHOWING 1-10 OF 46 REFERENCES
    Inhibition of Pancreatic Carcinoma Growth Through Enhancing ω-3 Epoxy Polyunsaturated Fatty Acid Profile by Inhibition of Soluble Epoxide Hydrolase
    • 8
    Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis
    • 220
    • Highly Influential
    • PDF
    Inhibition of soluble epoxide hydrolase modulates inflammation and autophagy in obese adipose tissue and liver: Role for omega-3 epoxides
    • 117
    • PDF
    Inhibition of soluble epoxide hydrolase ameliorates hyperhomocysteinemia-induced hepatic steatosis by enhancing β-oxidation of fatty acid in mice.
    • L. Yao, Boyang Cao, +14 authors Y. Zhu
    • Chemistry, Medicine
    • American journal of physiology. Gastrointestinal and liver physiology
    • 2019
    • 7
    Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo
    • 65
    • PDF
    Advances in Our Understanding of Oxylipins Derived from Dietary PUFAs.
    • 228
    • PDF
    Arachidonic Acid-metabolizing Cytochrome P450 Enzymes Are Targets of ω-3 Fatty Acids*
    • 305
    • PDF
    Characterization of 5,6- and 8,9-Epoxyeicosatrienoic Acids (5,6- and 8,9-EET) as Potent in Vivo Angiogenic Lipids*
    • 148
    • PDF